On July 23, 2026, an FDA advisory panel voted 8-6 with one abstention to recommend placing three injectable peptides — BPC-157, TB-500, and KPV — on the agency's list of substances considered safe for pharmacy compounding. The vote by the Pharmacy Compounding Advisory Committee (PCAC) is not binding on the FDA, but the agency typically follows such recommendations. The panel was scheduled to vote on three additional peptides the following day, July 24, as part of a two-day meeting covering seven peptides in total.

To understand why this matters, it helps to know what pharmacy compounding is. Under a provision of federal law known as Section 503A, pharmacists can prepare customized medications from bulk drug substances — raw ingredients — that appear on the FDA's "503A Bulks List." Think of this list as a fast track: if a substance is on it, compounding pharmacies can produce and distribute that medication without going through the full new drug approval process, which normally requires years of clinical trials and safety testing.

The PCAC's July 23–24 meeting addressed whether seven peptides should join that list: BPC-157 (in both its free base and acetate forms), TB-500 (free base and acetate), KPV (free base and acetate), MOTs, and Semax. The specific vote for BPC-157 concerned whether BPC-157 acetate should be placed on the list; KPV was subject to a separate vote covering both forms. BPC-157, a 15-amino acid peptide also known as Bepecin or PL-14736, was discussed in the context of potential use for ulcerative colitis. BPC-157, TB-500, and Semax are widely popular among fitness enthusiasts and biohackers.

The panel's recommendation arrives against sharp internal disagreement at the FDA. Agency staff scientists gave highly critical reviews of BPC-157, TB-500, and other peptides, stating there was little data to support their safe use for medical purposes. The FDA has warned that compounded drugs containing BPC-157 may pose immunogenicity risks — meaning the body's immune system could react against the drug in harmful ways — for certain routes of administration. The agency has separately warned Americans about the risks of injecting BPC-157 and TB-500. Regarding KPV, the FDA stated it "lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if" administered. The FDA maintains a public information page titled "Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks" that addresses both BPC-157 and KPV.

The committee's composition became a point of contention. Before the July 23 meeting, more than half a dozen people with connections to the peptide industry were added to the advisory panel, including doctors, pharmacists, and consultants working in the field. Panel members with backgrounds in academia mostly voted against the peptides, while those with industry connections largely voted in favor.

Dr. Elizabeth Rebello of the University of Texas MD Anderson Center expressed concern that the panel was "responding to a market-induced demand rather than a decision based in solid science." David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, voted yes on BPC-157, stating it was "time to put this decision back in the hands of the patient, the physician and the pharmacist."

Health Secretary Robert F. Kennedy Jr. has described himself as a "big fan" of peptides and vowed to overturn FDA restrictions on them that were put in place under Joe Biden. Peptide supporters include podcaster Joe Rogan and longevity influencer Gary Brecka, who supports RFK Jr.'s "Make America Healthy Again" agenda and sells peptides through his website. The June 2026 restrictions that Kennedy has targeted were themselves the subject of an earlier wave of public attention, with AP reporting in late June that the FDA had cautioned Americans about injection risks.

The broader context here involves a collision between two regulatory philosophies. The compounding pharmacy pathway under 503A was designed as a narrow exception for individualized patient needs, not a parallel track for mass distribution of substances that have not cleared the drug approval process. If the FDA follows the panel's recommendation, BPC-157, TB-500, and KPV would become available through compounding pharmacies without the clinical trial data that the agency's own staff scientists say is insufficient. If the FDA declines to follow the advice, it would set up a direct conflict with a Health Secretary who has made peptide access a personal priority.

The split vote and the abstention reflect a committee genuinely divided along professional fault lines. The correlation between industry affiliation and a yes vote, versus academic affiliation and a no vote, raises familiar questions about advisory committee capture — a concern that has surfaced in previous FDA controversies involving opioid prescribing guidelines and medical device approvals. What distinguishes this case is the extent to which the panel's membership was reshaped immediately before the vote, and the degree to which a cabinet-level official has publicly committed to a predetermined outcome before the scientific review concluded.

The panel's remaining agenda adds another layer. Three more peptides were scheduled for votes on July 24, including MOTs and Semax. The trajectory of those votes will indicate whether the July 23 result was driven by the specific substances involved or reflects a broader shift in the committee's posture toward compounding access. Either outcome will shape how the FDA ultimately acts on the full set of recommendations, and how Kennedy's publicly stated intentions interact with the agency's deliberative process.